e102 january 13, 2009 us intellectual property and licensing fred farina asst. vice president office...
Post on 21-Dec-2015
222 views
TRANSCRIPT
E102January 13, 2009
US Intellectual Property and Licensing
Fred FarinaAsst. Vice President
Office of Technology Transfer
E102January 13, 2009
E102January 13, 2009
• Founded in 1891• ~2,000 students
(900 undergraduate + 1100 graduate)
• 280 professors and 130 research faculty
• 5,300 engineers/scientist at JPL• 32 Nobel Prize Recipients among
faculty and alumni• 72 members of the NAS
• 35 members of the NAE
• $180M in Research Funding
California Institute of Technology
E102January 13, 2009
The Jet Propulsion Laboratory
Founded in the 1930’s when Caltech Founded in the 1930’s when Caltech Professor Theodore von Karman Professor Theodore von Karman conducted pioneering work on rocket conducted pioneering work on rocket propulsion.propulsion.
Chartered to Conduct Unmanned Chartered to Conduct Unmanned Robotic Exploration of the Solar SystemRobotic Exploration of the Solar System
Federally Funded R&D NASA Facility Federally Funded R&D NASA Facility operated by the Caltechoperated by the Caltech
Annual Budget - Over $1 BillionAnnual Budget - Over $1 Billion
5200 Employees5200 Employees 1/3 PhDs, 1/3 MS, 1/3 BS & Other1/3 PhDs, 1/3 MS, 1/3 BS & Other
Smart Lander Sample Return
Bulldozer
Mars Express
Smart Rover
Reconnaissance Orbiter
MarsMars
E102January 13, 2009
Scientists Invent in Research Labs
Invention Disclosuresto Technology Transfer Office
Evaluation of Inventions/Patent Filing Decisions
Technology Licensing
Startup CreationEstablished Company
OTT’sActivities
E102January 13, 2009
Start-up Report for the Past Decade (1995-2005)
Definition of Start-up*:
License to Caltech IP Caltech has equity interest prior to series A Company had to raise not less than $500K
* Definition more selective than previous years
E102January 13, 2009
Categories
• AS = Asset Sale A sale of Company for less than FMV• T = Terminated Inactive, IP returned• F = Failed Liquidated, IP no longer utilized
• ACQ = Acquisition IP acquired, shares sold by CIT• IPO = IPO Public company (IPO)
• ACT = Active In prototype devpmnt or prods. sales
E102January 13, 2009
Number of Start-ups: 78(over 100 using looser definition)
37% VC backed 3Fs, Angels, Small Independent Investors, Small
Public Companies
E102January 13, 2009
0
10
20
30
40
50
AS+T+F ACQ+IPO ACT
Failed
Success
ACT
• AS = 5• T= 5• F= 8
• ACQ =12• IPO= 5
• ACT =43
23% 22%
55%
E102January 13, 2009
Interesting Facts
Companies with products in marketplace: 23
Companies w/ sales > $1M/yr: 13 (8 w/ royalty obligations)
14% of Companies do not use the licensed technology
E102January 13, 2009
Category ACT (43)
8 companies with significant upside potential 16% outside of California 53% in Pasadena Total # of employees > 1,000 # of employees in Pasadena > 500 Much higher number if incl. IPO + ACQ
E102January 13, 2009
Caltech OTT in Tech Transfer Elite
A Global Analysis of University Biotechnology Transfer and Commercialization, includes the Milken Institute university Technology Transfer and Commercialization Index, which ranks universities at their ability to take world-class research and turn it into licensing income and business startups.
The top five are:1. Massachusetts Institute of Technology 2. University of California system 3. California Institute of Technology 4. Stanford University 5. University of Florida
E102January 13, 2009
Caltech OTT in Tech Transfer Elite
Five Universities You Can Do Business WithFrom: Inc. Magazine, February 2006
“ … Just five schools, in fact, constitute the elite of the technology transfer world. They are Berkeley, Caltech, Stanford, MIT, and Wisconsin. The list of universities reporting new discoveries changes from one year to the next, but each of these five schools consistently garners around 100 patents per year.”
“… Along with teaching and doing research, they seem to be in the business of inventing companies.”
“… Administrators at the Big Five play their part in nurturing tech transfer by resisting the temptation to monitor and regulate business relationships aggressively.”
E102January 13, 2009
Portable Inexpensive Personal Medicine Devices (Scherer)
E102January 13, 2009
Dendrimer Nanotechnology for Water Purification (Diallo)
E102January 13, 2009
Remote Measurement of Cardiac Waveforms (McGrath, JPL)
E102January 13, 2009
New CFx Batteries: Primary and Rechargeable (Yazami)
E102January 13, 2009
Micropumps for Chip Cooling & Biomed. Apps. (Gharib)
E102January 13, 2009
Eye-Predict (Koch)
E102January 13, 2009
Real-Time Micro-Arrays (Hassibi)
E102January 13, 2009
E102January 13, 2009
Intellectual Property Primer
• Patents
• Copyright
• Trade Secret
• Trademarks
• Trade Dress
E102January 13, 2009
US Patent Laws and Regulations
• 35 USC
• 37 CFR
• MPEP
“The Congress shall have power … To promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries…” U.S. Constitution, Article I, Section 8
E102January 13, 2009
For the Patentee:
Reward the Patentee with the right to exclude others from making, using, selling, offering to sell, in the US, or importing into the US, the patented invention.
US Patent’s Main Purposes
E102January 13, 2009
For Society:
Put the public in intellectual possession of the invention so that it can (1) benefit from the invention after the patent has expired, (2) improve on the invention, and (3) design around the claims
US Patent’s Main Purposes
E102January 13, 2009
The right to exclude others from making, using, offering for sale or selling the invention.
What is a Patent?
E102January 13, 2009
The right to make, use, offer for sale or sell the patented invention.
What a Patent is NOT
E102January 13, 2009
• Inventor = One who conceived the claimed invention
(Not one who merely reduces the invention to practice).
Inventorship
E102January 13, 2009
• Inventor owns her/his inventions
• However, Universities/Companies have employees sign Patent Agreement = Obligation to assign inventions to employer.
Ownership of Inventions/Patents
E102January 13, 2009
• A process (software, chemical process)• A machine (photocopier)• An article of manufacture (laser)• A composition of matter (chemicals, isolated genes)
“Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” 35 USC § 101
What is Patentable?
E102January 13, 2009
An Invention Must Be…
• Useful• Novel• Nonobvious
… to be patentable.
E102January 13, 2009
• Provisional• Nonprovisional (utility)
• Plant • Design
Types of Patents
E102January 13, 2009
• 1 year pendency• Never Issue• No Claims Required• Meet requirements of 35 USC § 112
Provisional Patent Applications
E102January 13, 2009
Anywhere•Printed Publication• Patented
In the U.S. • On sale / Offered for Sale• In Public Use
These events, if they occur more than one year before filing, create a Statutory Bar:
35 USC § 102(b)
Statutory Bars
E102January 13, 2009
• First to File• Paris Convention• Patent Cooperation Treaty (PCT)• Can be filed within 1 year of priority
Patenting Outside the US
E102January 13, 2009
• Drawing(s) (only required if necessary to understand the invention)
• Specification (description of the invention)
• Claim(s) (define intellectual property/scope of patent)
Patent Application
E102January 13, 2009
• Title of the Invention• Cross Reference to related applications (if any)• Statement of federally sponsorship• Background of the Invention• Brief Summary of the Invention• Brief description of drawing(s) (if any)• Detailed Description of the Invention•Abstract of the disclosure•Sequence listing (if any)
The Specification
E102January 13, 2009
• Written Description
• Enablement
• Best Mode
35 USC § 112, ¶ 1
Specification Requirement
E102January 13, 2009
1. A method for identifying a chemical analyte, wherein said chemical analyte is a biomolecule, using a sensor array, said method comprising:
(a) providing a sensor array, wherein each sensor comprises a conductive region and a nonconductive organic polymer region;
(b) contacting said biomolecule with said sensor array to produce a response; and
(c) analyzing said response thereby identifying said biomolecule. measuring apparatus.
U.S. Patent 6,331,244 to Lewis , et al.
Claims
E102January 13, 2009
• Conception• Reduction to Practice
(actual or constructive)• Filing Application• Office Action (rejection)• Response• Allowance
The Patent Process
E102January 13, 2009
U.S. Filing
Office Action
Response
Final Office Action
Appeal
Patent Issues
Priority Filing(e.g.,
provisional)
Publication at 18 months
Patent Prosecution
E102January 13, 2009
Government Publications•35 United States Code (35 USC)
(http://www.access.gpo.gov/uscode/title35/title35.html)•37 Code of Federal Regulations (37 CFR)
(see Appendix R of the MPEP below)•Manual of Patent Examination Procedure (MPEP)
(http://www.uspto.gov/web/offices/pac/mpep/mpep.htm)
Key Web Sites•http://www.uspto.gov•http://www.european-patent-office.org•http://www.law.emory.edu/fedcircuit/
Court decisions by the U.S. Court of Appeals, Federal Circuit
Patent Resources
E102January 13, 2009
Prospective licensee evaluates technology, (under NDA if necessary) Licensee expresses willingness to undertake commercialization of invention Negotiation of terms of the licenseBoilerplate agreement provides legal framework of the agreement Closing the deal Managing the relationship with the licensee
The Licensing Process
E102January 13, 2009
Upfront fees Minimums Royalty rate Equity Diligence and Milestones Patent Costs
Main Terms Subject to Negotiations
E102January 13, 2009
Special case of the Option: An option gives the right to acquire a license during the option period
Exclusive: agreement not to grant further licenses.
May be limited time, territory and field
Implied obligation to exploit
Nonexclusive: licensor may grant other licenses
Types of License Agreements
E102January 13, 2009
A License is an enforceable contract
Licensor waves its right to exclude licensee to make, use or sell patented invention, in exchange for consideration (usually financial)
Can be based on patents, know-how or combination
What is a License
E102January 13, 2009
• Preamble:
Identify the parties
Effective date
Anatomy of a License
E102January 13, 2009
• Definitions:
Defines terms essential to the agreement
Avoids ambiguity from inaccurate repetition
Aids in achieving conciseness and clarity
Anatomy of a License
E102January 13, 2009
• Grant:
Character of license: exclusive, non-exclusive
Make, use, sell, offer for sale, Import: separable rights
Licensed Patents Rights
Anatomy of a License
E102January 13, 2009
• Grant (cont’d):
Geographic scope of license grant
Term of the grant (implied life of patents)
Right to sublicense (must be explicit)
Anatomy of a License
E102January 13, 2009
• Patent Prosecutions and Patent Costs:
Responsible party to prosecuting patent apps.
Payment of patent costs
Schedule for reimbursement of patent costs
Anatomy of a License
E102January 13, 2009
• Royalty:
Consideration for the license
Upfront fees
Royalty rate (e.g., percentage of sales)
Minimum annual royalty
Escalation provision
Paid-up
Anatomy of a License
E102January 13, 2009
• Equity Interest:
Startups only
Number of shares of common stock, or percentage of total number
Anatomy of a License
E102January 13, 2009
• Due Diligence:
Minimum standard effort to to commercialize
Milestones: funding level deadline for first commercial sale Minimum annual sales
Anatomy of a License
E102January 13, 2009
• Royalty Reporting:
Record keeping
Audit of records: licensor entitled to audit
Reports by licensee of royalties due (periodic, provide payment at time of report, post-termination report)
Anatomy of a License
E102January 13, 2009
• Infringement by Third Party:
Nonexclusive licensee: No right to bring suit on its own
Exclusive licensee
May bring suit on its own
Licensor is indispensable party
Anatomy of a License
E102January 13, 2009
• Term and Termination:
Absent term: life of patents
Termination on breach Material breach only to heart of agreement Notice and cure period Automatic vs. second notice Licensee termination without cause (minimums)
Anatomy of a License
E102January 13, 2009
• Net Present Value and other calculations Complicated Unreliable Crystal ball often more effective
• Early stage: many unknowns by definition
Determining the Value of an Invnetion
E102January 13, 2009
• The market drives the value• IP is worth whatever a buyer is willing to pay for it
Negotiation
Determining the Value of an Invnetion
E102January 13, 2009
Rule of thumb: a share of 25% of profits for the licensor is generally accepted as reasonableHowever, using profits as a basis for royalties is problematic (many accounting ways of representing costs)Net sales are commonly used as basis for royalty payments (e.g., 4% of net sales).
Royalty Rate Determination
E102January 13, 2009
Licensees know best their profit margin When negotiating, let licensee make first offer U.S. courts have awarded royalty rates varying from 2 % to 20% of the selling price of infringing products
Royalty Rate Determination